Viva Biotech Holdings (1873.HK) Stock
Viva Biotech Holdings, an investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, including protein expression, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacology and DMPK; chemistry services, such as medicinal and synthetic chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; and antibody/biologics research and development services comprising recombinant protein expression platform, antibody discovery and affinity maturation, assay platform, antibody production and identification platform, and antigen-antibody structural resolution platform solutions.
Valuation
Financials & Margins
Latest News
Valuation & Return Ratios
Peer Comparison
About Viva Biotech Holdings
Viva Biotech Holdings, an investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, including protein expression, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacology and DMPK; chemistry services, such as medicinal and synthetic chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; and antibody/biologics research and development services comprising recombinant protein expression platform, antibody discovery and affinity maturation, assay platform, antibody production and identification platform, and antigen-antibody structural resolution platform solutions. It also offers PROTAC/molecular glue services, including protein preparation and complex structure determination, ADME & PK/PD studies of PROTAC molecules, and XDC platforms, such as XDC conjugation and quality study, and XDC chemistry research and development. In addition, the company offers contract development and manufacturing services comprising integrated services for small molecule active pharmaceutical ingredients, formulation development and production services, and pharmaceutical analysis services, as well as CMC filing, global filing registration support, and other services. Further, it provides research services. The company was incorporated in 2008 and is headquartered in Shanghai, China.
Viva Biotech Holdings (1873.HK) stock trades at $1.58 with a market capitalization of $3.26B. The stock is valued at a price-to-earnings (P/E) ratio of 15.80, price-to-book of 0.72, price-to-sales of 1.89. Over the past 52 weeks the stock has ranged between $1.04 and $3.27, and currently trades 51.7% below its 52-week high.
On profitability, Viva Biotech Holdings generates a return on equity (ROE) of 6.88%, an operating margin of 8.63%, a net profit margin of 12.71%.
Official website: www.vivabiotech.com.cn